Pharma BD Deal Intelligence
A collapsed bet: Roche paid Xencor $120M upfront for XmAb24306, an unusually rich preclinical price, but Genentech removed efbalropendekin alfa from its pipeline in January 2025 and moved to terminate the deal entirely by March 2026.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Xencor inks $120M deal with Roche for preclinical bispecific; the unusually rich upfront for a preclinical asset reflects Roche's appetite for bispecific and…
Roche's Genentech and Xencor form $460M deal for cytokine therapeutics, validating engineered IL-15 as a strategic priority for combination immuno-oncology…
On March 4, 2026 Xencor disclosed that Genentech (Roche) will terminate the collaboration and license agreement effective September 4, 2026, after Roche…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Genentech (Roche Group) and Xencor entered a research and license agreement, announced February 5, 2019 and closed effective March 8, 2019 after HSR clearance, to develop novel IL-15 cytokine therapeutics led by XmAb24306 (later RG6323 / efbalropendekin alfa), an IL-15/IL-15Ra-Fc complex built on Xencor's bispecific Fc and Xtend technology. Xencor received $120M upfront and was eligible for up to $160M in clinical milestones per program plus additional development milestones (more than $1.5B in aggregate potential across the IL-15 portfolio), and could share 45% of net profits/losses on XmAb24306. The partnership subsequently unwound: Xencor opted out of the 45% cost-sharing in the first half of 2024, leaving Genentech as sole funder; Roche removed efbalropendekin alfa from its development pipeline in January 2025; and on March 4, 2026 Xencor disclosed that Genentech will terminate the collaboration and license agreement effective September 4, 2026 — the lead asset never advanced to a profit-sharing commercial stage.
$23.0B Global PD-(L)1 / I-O backbone market 2022 (combinations context)
Cytokine immunotherapy aims to expand and activate effector immune cells (CD8 T-cells, NK cells) to amplify response to checkpoint inhibitors. IL-15 is biologically attractive because it drives CD8 and NK expansion without activating immunosuppressive regulatory T-cells, making it a candidate I-O backbone enhancer for PD-(L)1 non-responders.
The IL-15 immuno-oncology space in 2019 was crowded with engineered cytokines aimed at fixing the narrow therapeutic window of native IL-2/IL-15. Key competitors at deal time included Nektar's NKTR-255 (IL-15Ra-conjugated polymer), ImmunityBio's N-803 (now Anktiva, IL-15 superagonist fusion — ultimately FDA-approved April 2024 for BCG-unresponsive NMIBC), Altor BioScience's ALT-803, and Cugene/Synthorx engineered IL-2 programs. Xencor's XmAb24306 differentiated as an IL-15/IL-15Ra heterodimeric Fc fusion engineered for half-life extension and reduced peripheral toxicity. Genentech's $120M upfront for a preclinical asset was unusually rich — SVB Leerink's Jonathan Chang attributed it to Roche's strategic interest in expanding bispecifics combinations. XmAb24306 has progressed to Phase 1 (NCT04250155) as monotherapy and in combination with atezolizumab in solid tumors and is now branded efbalropendekin alfa (RG6323/RO7296682). The asset remains in development as of 2024 with no DLTs identified, but commercial potential depends on differentiation versus Anktiva (the only approved IL-15 agent) and the broader cytokine field's mixed clinical readouts.
Agreement effective March 8, 2019; $120M upfront due within 30 days.
Xencor exited co-development in H1 2024, leaving Genentech sole funder of the IL-15 program.
Roche removed the IL-15 lead asset (XmAb24306 / RG6323) from its development pipeline in Jan 2025.
Xencor disclosed on March 4, 2026 that Genentech will terminate the collaboration and license agreement effective September 4, 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Xencor, Inc. (this deal) | 2019 | $1.6B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Oncology deals